Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 12:23 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 3,868 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

NCT01192139
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
saxagliptin, metformin XR, saxagliptin + metformin XR (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Nov 1, 2026, 12:23 PM EST
Completed Early Phase 1 Interventional

Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

NCT02484053
View directory record Official record
Conditions
Hematologic Disorders, Oncologic Disorders, Rheumatologic Disorders
Interventions
Rituximab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Nov 1, 2026, 12:23 PM EST
Completed Not applicable Interventional

HIV Testing and Brief Alcohol Intervention for Young Drinkers in the Emergency Department

NCT01573065
View directory record Official record
Conditions
Alcohol Consumption, Sexual Risk Behaviors
Interventions
Counseling intervention with rapid HIV testing
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 2 Interventional Results available

A Study of Patients Receiving High-Dose Rate Brachytherapy

NCT00924027
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
Interventions
High Dose Radiation (HDR) Brachytherapy, MRI, CT, PET Scan
Radiation · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions

NCT00829673
View directory record Official record
Conditions
Healthy
Interventions
Dexmethylphenidate Hydrochloride
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Nov 1, 2026, 12:23 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Flavanol Absorption, Metabolism and Excretion From Fruit-based Drinks and Other Food Matrixes

NCT03526094
View directory record Official record
Conditions
Healthy
Interventions
Flavanols-capsules, Flavanol-banana blend, Flavanol-high protein drink, Flavanol-berry blend, Flavanol-sports drink, Flavanol-peanut butter toast, Flavanol-oats, Flavanol-yogurt, II- Flavanol drink, II- Flavanol drink + banana blend
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Nov 1, 2026, 12:23 PM EST
Completed No phase listed Observational

Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood

NCT02482051
View directory record Official record
Conditions
Bacteremia, Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
7 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefadroxil 500 mg Capsules Under Fasting Conditions

NCT00834275
View directory record Official record
Conditions
Healthy
Interventions
Cefadroxil 500 mg Capsules, DURICEF® capsules 500 mg
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Nov 1, 2026, 12:23 PM EST
Completed No phase listed Observational

Brain Perfusion and Hemodynamic Stability in Patients Undergoing Radiofrequency Ablation of Ventricular Tachycardia

NCT01695551
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Data Collection Forms
Other
Lead sponsor
Dhanunjaya Lakkireddy, MD, FACC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Nov 1, 2026, 12:23 PM EST
Recruiting Phase 1Phase 2 Interventional

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

NCT07736937
View directory record Official record
Conditions
Ovarian Cancer
Interventions
TUB-040 + Carbo + BEV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Los Angeles, California • East Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

NCT01119677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Avonex
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefprozil 500 mg Tablets Under Fasting Conditions

NCT00840281
View directory record Official record
Conditions
Healthy
Interventions
Cefzil® 500 mg tablets, Cefprozil 500 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 4 Interventional Results available

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial

NCT03472495
View directory record Official record
Conditions
Atrial Fibrillation and Flutter
Interventions
Diltiazem Oral Product, Diltiazem Injectable Product
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 3 Interventional

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

NCT05134012
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Drug
Lead sponsor
MedTrace Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Iowa City, Iowa • Rochester, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 1, 2026, 12:23 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

NCT05555030
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
Device · Diagnostic Test
Lead sponsor
New Day Diagnostics
Network
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Anaheim, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 1, 2026, 12:23 PM EST
Not listed Not applicable Interventional

Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures

NCT03744728
View directory record Official record
Conditions
Bloodstream Infection
Interventions
Accelerate PhenoTest™ BC kit, Standard of Care
Diagnostic Test
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Nov 1, 2026, 12:23 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Health Benefits of a 21-day Daniel Fast

NCT01378767
View directory record Official record
Conditions
Effects of Krill Oil on Human Health
Interventions
Krill oil supplementation
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Food-Effect Pharmacokinetic Study of PL2200

NCT01244100
View directory record Official record
Conditions
Healthy
Interventions
PL2200 fasted, PL2200 fed
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Nov 1, 2026, 12:23 PM EST
Completed Not applicable Interventional Results available

A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia

NCT02189161
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia (AIN), High-grade Squamous Intraepithelial Lesions (HSIL)
Interventions
Radiofrequency Ablation (Barrx™)
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Nov 1, 2026, 12:23 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

FFA-Induced Hypertension and Endothelial Dysfunction

NCT00589888
View directory record Official record
Conditions
Endothelial Dysfunction, Hypertension
Interventions
Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Nov 1, 2026, 12:23 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating Individual Differences in Speech Motor Skills in Neurotypical Speakers and Persons With Disordered Speech

NCT07459803
View directory record Official record
Conditions
Stuttering, Developmental, Dyslexia, Healthy Participants
Interventions
Unpredictable auditory feedback perturbation: 2 behavioral sessions, Unpredictable auditory feedback perturbation during tCS: 3 behavioral sessions, Sustained F1 auditory feedback perturbation, Sustained F0 auditory feedback perturbation, Reflexive somatosensory perturbation, Anodal tCS targeting pSTG and vSSC, Anodal tCS targeting left or right vPMC, Sham tCS targeting pSTG or vSSC, Sham tCS targeting left vPMC or right vPMC
Behavioral · Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 1, 2026, 12:23 PM EST
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

NCT05255107
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function

NCT02959138
View directory record Official record
Conditions
Inflammatory Disease
Interventions
Lanraplenib.
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Nov 1, 2026, 12:23 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts

NCT04652648
View directory record Official record
Conditions
Covid19, Hydroxychloroquine, Coronavirus Infection, Transmission, Prophylaxis
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Bryn Mawr Hospital
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Bryn Mawr, Pennsylvania • Paoli, Pennsylvania • Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Nov 1, 2026, 12:23 PM EST